| Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor F Fischetti, P Durigutto, V Pellis, A Debeus, P Macor, R Bulla, F Bossi, ... Blood 106 (7), 2340-2346, 2005 | 416 | 2005 |
| Dynamics of complement activation in aHUS and how to monitor eculizumab therapy M Noris, M Galbusera, S Gastoldi, P Macor, F Banterla, E Bresin, ... Blood, The Journal of the American Society of Hematology 124 (11), 1715-1726, 2014 | 331 | 2014 |
| Complement in human diseases: lessons from complement deficiencies M Botto, M Kirschfink, P Macor, MC Pickering, R Würzner, F Tedesco Molecular immunology 46 (14), 2774-2783, 2009 | 324 | 2009 |
| In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab P Macor, C Tripodo, S Zorzet, E Piovan, F Bossi, R Marzari, A Amadori, ... Cancer research 67 (21), 10556-10563, 2007 | 181 | 2007 |
| A non–complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome C Agostinis, P Durigutto, D Sblattero, MO Borghi, C Grossi, F Guida, ... Blood, The Journal of the American Society of Hematology 123 (22), 3478-3487, 2014 | 144 | 2014 |
| The development of atypical hemolytic uremic syndrome depends on complement C5 EG de Jorge, P Macor, D Paixao-Cavalcante, KL Rose, F Tedesco, ... Journal of the American Society of Nephrology 22 (1), 137-145, 2011 | 132 | 2011 |
| Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement‐regulatory proteins CD55 and CD59 F Ziller, P Macor, R Bulla, D Sblattero, R Marzari, F Tedesco European journal of immunology 35 (7), 2175-2183, 2005 | 112 | 2005 |
| Complement as effector system in cancer immunotherapy P Macor, F Tedesco Immunology letters 111 (1), 6-13, 2007 | 104 | 2007 |
| NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation F Pozzo, T Bittolo, F Arruga, P Bulian, P Macor, E Tissino, B Gizdic, ... Leukemia 30 (1), 182-189, 2016 | 103 | 2016 |
| Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery PL Meroni, P Macor, P Durigutto, L De Maso, M Gerosa, M Ferraresso, ... Blood, The Journal of the American Society of Hematology 127 (3), 365-367, 2016 | 78 | 2016 |
| Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice P Macor, E Secco, N Mezzaroba, S Zorzet, P Durigutto, T Gaiotto, ... Leukemia 29 (2), 406-414, 2015 | 76 | 2015 |
| Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications F Tedesco, MO Borghi, M Gerosa, CB Chighizola, P Macor, PA Lonati, ... Frontiers in immunology 9, 374767, 2018 | 65 | 2018 |
| Complement activated by chimeric anti–folate receptor antibodies is an efficient effector system to control ovarian carcinoma P Macor, D Mezzanzanica, C Cossetti, P Alberti, M Figini, S Canevari, ... Cancer research 66 (7), 3876-3883, 2006 | 56 | 2006 |
| Simple scale-up of recombinant antibody production using an UCOE containing vector S Boscolo, F Mion, M Licciulli, P Macor, L De Maso, M Brce, MN Antoniou, ... New Biotechnology 29 (4), 477-484, 2012 | 55 | 2012 |
| The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies R Marzari, D Sblattero, P Macor, F Fischetti, R Gennaro, JD Marks, ... European journal of immunology 32 (10), 2773-2782, 2002 | 55 | 2002 |
| Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5 P Macor, P Durigutto, L De Maso, C Garrovo, S Biffi, A Cortini, F Fischetti, ... Arthritis & Rheumatism 64 (8), 2559-2567, 2012 | 54 | 2012 |
| Cubosomes stabilized by a polyphosphoester-analog of Pluronic F127 with reduced cytotoxicity M Fornasier, S Biffi, B Bortot, P Macor, A Manhart, FR Wurm, S Murgia Journal of colloid and interface science 580, 286-297, 2020 | 51 | 2020 |
| Cubosomes for in vivo fluorescence lifetime imaging S Biffi, L Andolfi, C Caltagirone, C Garrovo, AM Falchi, V Lippolis, ... Nanotechnology 28 (5), 055102, 2016 | 49 | 2016 |
| C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function F Bossi, L Rizzi, R Bulla, A Debeus, C Tripodo, P Picotti, E Betto, P Macor, ... Blood, The Journal of the American Society of Hematology 113 (15), 3640-3648, 2009 | 49 | 2009 |
| New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats P Durigutto, C Grossi, MO Borghi, P Macor, F Pregnolato, E Raschi, ... Haematologica 104 (4), 819, 2019 | 46 | 2019 |
